

14 May 2025

Update to Cleansing Notice and additional cleansing notice

Enlitic, Inc. (ASX: ENL) ("the Company" or "Enlitic") refers to its cleansing notice dated 12 May 2025 and released to ASX on the same date ("Cleansing Notice"). Enlitic notes that the reference in the Cleansing Notice to "145,792,651 shares of common stock (and equivalent CHESS Depository Interests)" should instead refer to "139,931,637 shares of common stock (and equivalent CHESS Depository Interests)".

In addition, Enlitic gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) ("Corporations Act") (as modified by ASIC Instrument 2025/180 (as applicable)) regarding the issue of 5,861,014 shares of common stock (and equivalent CHESS Depository Interests) ("Placement Shares") at a price of \$0.04 per Placement Share issued today in accordance with the announcements made by Enlitic on Monday, 5 May 2025.

As at the date of this notice, Enlitic confirms that:

- (a) the Placement Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, Enlitic has complied with:
 - (i) section 601CK of the Corporations Act as it applies to Enlitic; and
 - (ii) sections 674 and 674A of the Corporations Act; and
- (d) as at the date of this notice, there is no "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be set out in this notice.

– ENDS –

This announcement was authorised for release by the Company Secretary.

Enquiries

Enlitic Investor Relations

Australia:

invest_au@enlitic.com

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic's products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

Enlitic's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.